| Ticker Details |
Denali Therapeutics Inc.
Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
|
| IPO Date: |
December 8, 2017 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$2.96B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.77 | 2.74%
|
| Avg Daily Range (30 D): |
$0.45 | 2.30%
|
| Avg Daily Range (90 D): |
$0.53 | 2.64%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.64M |
| Avg Daily Volume (30 D): |
1.38M |
| Avg Daily Volume (90 D): |
1.43M |
| Trade Size |
| Avg Trade Size (Sh.): |
68 |
| Avg Trade Size (Sh.) (30 D): |
60 |
| Avg Trade Size (Sh.) (90 D): |
62 |
| Institutional Trades |
| Total Institutional Trades: |
3,639 |
| Avg Institutional Trade: |
$2.74M |
| Avg Institutional Trade (30 D): |
$2.58M |
| Avg Institutional Trade (90 D): |
$2.61M |
| Avg Institutional Trade Volume: |
.11M |
| Avg Institutional Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.85M |
| Avg Closing Trade (30 D): |
$4.82M |
| Avg Closing Trade (90 D): |
$5.08M |
| Avg Closing Volume: |
148.32K |
|
|
| Financials |
| |
TTM |
Q1 2026 |
Q4 2025 |
|
Basic EPS
|
$-2.88
|
$-.69
|
$-.73
|
|
Diluted EPS
|
$-2.88
|
$-.69
|
$-.73
|
|
Revenue
|
$M
|
$M
|
$M
|
|
Gross Profit
|
|
|
|
|
Net Income / Loss
|
$-508.02M
|
$-128.45M
|
$-128.55M
|
|
Operating Income / Loss
|
$-547.12M
|
$-137.36M
|
$-137.37M
|
|
Cost of Revenue
|
|
|
|
|
Net Cash Flow
|
$330.68M
|
$182.3M
|
$114.36M
|
|
PE Ratio
|
|
|
|
|
|
|
